Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -22.87% is 73% above its 5-year average of -84.15%, near the high end of its 5-year range (-197.98%–-18.62%).
18.03% above its 12-month average of -27.90%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -41.32%.
EBITDA MARGIN
-22.87%
EBITDA MARGIN AVG TTM
-27.90%
EBITDA MARGIN AVG 3Y
-40.55%
EBITDA MARGIN AVG 5Y
-84.15%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.03%
CURRENT VS 3Y AVG
+43.60%
CURRENT VS 5Y AVG
+72.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.46M
EBITDA Margin
-75.46%
TTM Avg
-92.89%
3Y Avg
-421.55%
5Y Avg
-389.33%
Market Cap
$1.48M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49M
EBITDA Margin
-1231.39%
TTM Avg
-651.84%
3Y Avg
-512.06%
5Y Avg
-24032.93%
Market Cap
$1.51M
EBITDA Margin
-346.64%
TTM Avg
-376.56%
3Y Avg
-438.06%
5Y Avg
-395.70%
Market Cap
$1.20M
EBITDA Margin
-40873.19%
TTM Avg
-40873.19%
3Y Avg
-21172.28%
5Y Avg
-10780.34%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NEXGEL, Inc. (NXGL) | $1.40M | -22.87% | -27.90% | -40.55% | -84.15% |
| NewcelX Ltd. (NCEL)vs › | $1.39M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.37M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.46M | -75.46% | -92.89% | -421.55% | -389.33% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | N/A | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | -1231.39% | -651.84% | -512.06% | -24032.93% |
| Curis, Inc. (CRIS)vs › | $1.51M | -346.64% | -376.56% | -438.06% | -395.70% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | N/A | N/A | N/A | N/A |
Gross Margin
35.1%
EBITDA Margin
-22.9%
Operating Margin
-29.4%
Net Margin
-51.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -41.32% |
| 2026-03-31 | -29.66% |
| 2025-12-31 | -29.01% |
| 2025-09-30 | -20.89% |
| 2025-06-30 | -18.62% |
| 2025-03-31 | -23.20% |
| 2024-12-31 | -22.72% |
| 2024-09-30 | -20.54% |
| 2024-06-30 | -67.22% |
| 2024-03-31 | -63.35% |
| 2023-12-31 | -81.24% |
| 2023-09-30 | -47.26% |
| 2023-06-30 | -62.13% |
| 2023-03-31 | -137.42% |
| 2022-12-31 | -143.70% |
| 2022-09-30 | -177.82% |
| 2022-06-30 | -122.82% |
| 2022-03-31 | -197.98% |
| 2021-12-31 | -161.12% |
| 2021-09-30 | -173.43% |
| 2021-06-30 | -125.66% |
| 2021-03-31 | -184.64% |
| 2020-12-31 | -656.93% |
| 2020-09-30 | -200.83% |
| 2020-06-30 | -581.32% |
| 2020-03-31 | -207.92% |
| 2019-12-31 | -169.89% |
| 2019-09-30 | 28.57% |
| 2019-06-30 | -849.60% |
| 2019-03-31 | -448.06% |
| 2018-12-31 | -102.82% |
| 2018-09-30 | -191.38% |
| 2018-06-30 | -23.96% |
| 2018-03-31 | -54.44% |
| 2017-12-31 | -17.98% |
